Monthly Archives: May 2016

The E-Cigarettes Industry Fights Back Challenging the FDA in Federal Court

Posted by Ryan Blaney on May 16, 2016
E-Cigarettes, Food and Drug Law, HHS, Regulations / No Comments

e cig

Days after the publication of the Food and Drug Administration’s controversial final rule regarding e-cigarettes (and other nicotine-delivering products), a company called Nicopure Labs LLC filed a lawsuit challenging it in the U.S. District Court for the District of Columbia.  Nicopure seeks to have the rule vacated and declared unlawful, and has requested a preliminary injunction barring enforcement of the rule and prohibiting the FDA from taking any action under the rule pending resolution of the lawsuit.

The final rule, which will take effect on August 8, 2016 absent an injunction, grants the FDA authority to regulate electronic cigarettes and other vaping products and imposes rules on the industry that many insiders fear will leave it decimated.  These rules include banning sales to anyone younger than 18 years of age, requiring extensive warning labels on packing and — most significantly — subjecting all products (even those currently on the market) to the FDA approval process and the FDA’s reporting and recordkeeping requirements.  The price tag associated with the FDA approval process alone likely will pose an insurmountable barrier for the small vape shops, device manufacturers and e-liquid producers that currently drive most of the industry.

Nicopure, a Florida company that distributes battery-powered vaping devices and manufactures and distributes e-liquid, seeks to have the Final Rule vacated on several grounds.  First, Nicopure alleges that the deeming rule defines “tobacco product” so broadly that it constitutes an unreasonable construction of the authority granted under the Administrative Procedure Act (APA).  Additionally, Nicopure contends that the rule should be vacated as arbitrary and capricious in violation of the APA.  Finally, Nicopure brings a constitutional challenge, arguing that the rule violates the First Amendment by prohibiting manufacturers from “making truthful and nonmisleading statements regarding vaping devices, e-liquids and related products” and from “engaging in other forms of protected expression, including by distributing free samples of vaping devices or e-liquids.”

As of this writing, the FDA has not responded to Nicopure’s complaint, but the case (Nicopure Labs, LLC v. Food and Drug Administration, et al.,1:16-cv-00-878) will no doubt be closely watched by the rule’s proponents and detractors alike.

For more information you can contact Ryan Blaney or another member of Cozen O’Connor’s Health Law team.

 

Ryan Blaney

Ryan Blaney

Ryan represents health care and life sciences clients in a wide range of litigation, regulatory, and transactional matters, but has particular experience in the areas of privacy law compliance and health care fraud litigation. In his regulatory and transactional practice, Ryan serves public and private health care companies, academic medical centers, health systems, hospitals and physician organizations, manufacturers, medical devices, information technology and health plans

More Posts - Website

Tags: , , ,

Medical Marijuana in Pennsylvania: What Physicians Should Know

Posted by Chris Raphaely on May 09, 2016
DEA, DOH, Medicaid, Pennsylvania / No Comments

shutterstock_244196869On April 17, 2016, Governor Wolf signed Act 16 of 2016, making Pennsylvania the 24th state (plus the District of Columbia) to legalize marijuana for medical use. The full text of the act is available here.

Physicians, not surprisingly, will play a vital role in making medical marijuana available to Pennsylvanians, while ensuring patient safety in the process.  This is what they should know about Act 16: Continue reading…

Chris Raphaely

Chris Raphaely

Chris joined Cozen O’Connor’s Philadelphia office in 2014 as co-chair of the Health Care Practice Group. Prior to joining the firm, Chris served as deputy general counsel to Jefferson Health System and general counsel to the system’s accountable care organization and captive professional liability insurance companies.

More Posts

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,